Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China

This article was originally published in PharmAsia News

Executive Summary

The PharmAsia News Japanese earnings roundup is a periodic feature highlighting major developments from Japanese pharma quarterly calls and reports. The prior installment discussed recent developments at Shionogi & Co. Ltd. and Astellas Pharma Inc. ('Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning,' PharmAsia News, Aug. 2, 2011).

You may also be interested in...



Vertex's Cystic Fibrosis Drug Kalydeco Given Green Light By EU's Scientific Advisory Panel

Vertex's cystic fibrosis product Kalydeco is one of five new molecular entities given a positive opinion by Europe's Committee for Medicinal Products for Human Use on May 25, which also included Almirall's novel COPD therapy aclidinium and Novo Nordisk's recombinant Factor XIII.

Eisai Launches Mobile Phone Patient Compliance Site For Reflux Esophagitis

Eisai hopes to protect RE treatment Pariet/AcipHex (rabeprazole) from post-patent competition.

Japan Earnings Roundup: Astellas' Oncology Gains, Eisai Hit Hard, KHK Domestic Strength

Related Content

UsernamePublicRestriction

Register

SC078905

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel